Single-center Open Clinical Trial for Safety and Efficacyof Low alpha- beta-T CellHSCT after Donor-antigen Specific Clones Induced Deletion in Thalassemia

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025870

Enrollment

Unknown

Registered

2019-09-12

Start date

2019-08-29

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia

Interventions

Case series:Peripheral blood stem cells are cleared by alpha-t cells

Eligibility

Sex/Gender

All

Age

4 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Transfusion dependent thalassemia patients, i.e., TDT patients; 2. No 10/10 HLA compatible sibling or unrelated donor (A, B, C, DRB1 and DPB1 locus); 3. there were no 9-10 HLA compatible donors; 4. no >=7/10 HLA compatible unrelated umbilical cord blood; 5. Sign the informed consent.Only if all criteria are met.

Exclusion criteria

Exclusion criteria: 1. Left ventricular ejection fraction in 5000 patients; 4. accompanied by those deemed unsuitable by other doctors; 5. renal insufficiency, allergy, pregnancy and recent clinical trial participants.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactChunfu Li

Taixin Hospital

chunfu.li@gzcf-blood.com+86 18675865379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026